Shots:
Suresh Kannan discussed the latest semi-annual update to bring innovative revenue optimization and compliance solution for life sciences and high-tech innovators
He elaborated on the Fall 2022 product release, providing customers with tools to improve automation, efficiency, and profitability during economic uncertainty along with streamlined pricing communication
The interview gives an understanding of how…
Shots:
Whitney gave a brief on the partnership of Curebase with Digital Therapeutics Alliance to provide fit-for-purpose evidence standard for DTx product regulatory, reimbursement, and clinical acceptance
Whitney also elaborated on the Fit-for-Purpose Evidentiary standards and talked about why the DTx devices do not fit in the standards for medical devices by quoting some examples …
Shots:
Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting
Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials
This interview…
Shots:
Dr. Philip shared his views on the collaboration of Sernova with Evotec for iPSC-Based Beta cell replacement therapy to develop and commercialize a ‘Functional Cure’ for diabetes.
He also gave an overview on the benefits of Evotec’s iPSC-based insulin-producing beta cells on the next generation of Sernova’s Cell Pouch System
The interview discusses about how Sernova…
Shots:
Toni spoke about the CONNEQT Pulse the first dual blood pressure monitor with ATCOR’s SphygmoCor technology. The device is used for remote patient monitoring, home health, and clinical trials
She also elaborated about the data used for the pre-marketing submission with FDA. She explained the seven key vascular biomarkers that the device measures and…
Shots:
John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders
Under the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
Shots:
Johanna Contreras, Director of the Ambulatory Heart Failure Network & Diversity Mount Sinai Health System spoke about the initiation of this campaign and how it is empowering Latina women with heart failure to prioritize their heart health
Lupe, a woman diagnosed with heart failure, shared her experience of her life with heart failure and…
The 12th edition of the Pharma IPR Conference organized by Informa Markets will be held from 1-3 March 2023 in Mumbai. This is the only conference in India's pharmaceutical industry that focuses on Intellectual Property. The aim of this conference is to bring together all stakeholders in the pharma sector to discuss and deliberate on…
Weece Events is glad to invite you to attend the Global PHT Expo & Summit 2023 which is an International Conference & Exhibition on PHARMA, HEALTHCARE & TECHNOLOGY focusing on the Future of the Global Pharma & Healthcare Ecosystem in a digitally transforming world. The event is happening from 15-17th Feb 2023 at Hyatt Centric,…
Active Ingredient: Ibrutinib
Dosage Forms & Strengths:
Capsules: 70 mg and 140 mg
Tablets: 140 mg, 280 mg, 420 mg, and 560 mg
Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi)
First Approval: US (13 Nov 2013), EU (Oct 2014)
Revenue Analysis
Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…

